Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008–2011.
The DOI matches its Crossref record; 138 of the 138 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Candidemia is common and associated with high morbidity and mortality; changes in population-based incidence rates have not been reported. METHODS: We conducted active, population-based surveillance in metropolitan Atlanta, Georgia, and Baltimore City/County, Maryland (combined population 5.2 million), during 2008-2011. We calculated candidemia incidence and antifungal drug resistance compared with prior surveillance (Atlanta, 1992-1993; Baltimore, 1998-2000). RESULTS: We identified 2675 cases of candidemia with 2329 isolates during 3 years of surveillance. Mean annual crude incidence per 100 000 person-years was 13.3 in Atlanta and 26.2 in Baltimore. Rates were highest among adults aged ≥65 years (Atlanta, 59.1; Baltimore, 72.4) and infants (aged <1 year; Atlanta, 34.3; Baltimore, 46.2). In both locations compared with prior surveillance, adjusted incidence significantly declined for infants of both black and white race (Atlanta: black risk ratio [RR], 0.26 [95% confidence interval {CI}, .17-.38]; white RR: 0.19 [95% CI, .12-.29]; Baltimore: black RR, 0.38 [95% CI, .22-.64]; white RR: 0.51 [95% CI: .29-.90]). Prevalence of fluconazole resistance (7%) was unchanged compared with prior surveillance; 32 (1%) isolates were echinocandin-resistant, and 9 (8 Candida glabrata) were multidrug resistant to both fluconazole and an echinocandin. CONCLUSIONS: We describe marked shifts in candidemia epidemiology over the past 2 decades. Adults aged ≥65 years replaced infants as the highest incidence group; adjusted incidence has declined significantly in infants. Use of antifungal prophylaxis, improvements in infection control, or changes in catheter insertion practices may be contributing to these declines. Further surveillance for antifungal resistance and efforts to determine effective prevention strategies are needed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“All-cause in-hospital mortality of candidemia has been reported as high as 36% in the US.27,51,52”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [51]
In the citing paper
“Candidemia is one of the most common health care–associated BSIs in the United States, with all-cause in-hospital mortality of up to 30%.”
From Population-Based Active Surveillance for Culture-Confirmed Candidemia — Four Sites, United States, 2012–2016 (2019) · cites this paper as [6]
In the citing paper
“In population-based surveillance performed in the metropolitan areas of Atlanta, Georgia, and Baltimore, Maryland, candidemia incidence (primarily among adults) increased 10%–40% from the early 1990s and the late 2000s, which was followed by more recent reports of decreases in these areas (6,28–30).”
From Population-Based Active Surveillance for Culture-Confirmed Candidemia — Four Sites, United States, 2012–2016 (2019) · cites this paper as [6]
In the citing paper
“This contrasts with data from the early 1990s, when infants had the highest incidence (6), followed by substantial decreases by the late 2000s (26,28).”
From Population-Based Active Surveillance for Culture-Confirmed Candidemia — Four Sites, United States, 2012–2016 (2019) · cites this paper as [6]
In the citing paper
“The previously reported racial disparity in candidemia persisted in this surveillance period (6), with a 2.3 times higher incidence among blacks than among nonblacks.”
From Population-Based Active Surveillance for Culture-Confirmed Candidemia — Four Sites, United States, 2012–2016 (2019) · cites this paper as [6]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Bone, R. C., Balk, R. A., Cerra, F. B., Dellinger, R. P., Fein, A. M., Knaus, W. A., Schein, R. M. H., & Sibbald, W. J. (1992) · Chest · doi:10.1378/chest.101.6.1644 · Cited by 13,198 · cited 1×
“%) met criteria for sepsis [19].”
De Pauw, B., Walsh, T. J., Donnelly, J. P., Stevens, D. A., Edwards, J. E., Calandra, T., Pappas, P. G., Maertens, J., Lortholary, O., Kauffman, C. A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/588660 · Cited by 4,917
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496 · cited 1×
“Candida species are among the most common causes of BSIs and are associated with high morbidity and mortality, as well as increases in hospital cost and length of stay [1–5].”
An Intervention to Decrease Catheter-Related Bloodstream Infections in the ICU
Pronovost, P., Needham, D., Berenholtz, S., Sinopoli, D., Chu, H., Cosgrove, S., Sexton, B., Hyzy, R., Welsh, R., Roth, G., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061115 · Cited by 4,387 · cited 2×
“…dramatic declines in some central line– associated BSIs (CLABSIs), such as those associated with Staphylococcus aureus , following adherence to established central line insertion practices; however, similar dramatic declines have been less evident for CLABSIs due to Candida species [20, 24, 34–36].”
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174
Whiting, P., Rutjes, A. W., Reitsma, J. B., Bossuyt, P. M., & Kleijnen, J. (2003) · BMC Medical Research Methodology · doi:10.1186/1471-2288-3-25 · Cited by 3,592
Pappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191 · cited 1×
“shown to decrease risk of disease [21, 25–29].”
Boyle, J. P., Thompson, T. J., Gregg, E. W., Barker, L. E., & Williamson, D. F. (2010) · Population Health Metrics · doi:10.1186/1478-7954-8-29 · Cited by 1,309 · cited 1×
“Increases in common risk factors such as diabetes [30], ICU admissions [31, 32], or numbers of patients receiving immunosuppressive therapies [33] may have resulted in increases in the overall pool of patients at high risk for candidemia.”
Morrell, M., Fraser, V. J., & Kollef, M. H. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.9.3640-3645.2005 · Cited by 1,286
Attributable Mortality of Nosocomial Candidemia, Revisited
Gudlaugsson, O., Gillespie, S., Lee, K., Berg, J. V., Hu, J., Messer, S., Herwaldt, L., Pfaller, M., & Diekema, D. (2003) · Clinical Infectious Diseases · doi:10.1086/378745 · Cited by 1,140 · cited 2×
“0 %) between centres [2, 14, 18, 31] possibly because of lack of standardized criteria.”
Research works printed but not linked: 2
- 1992, Chest, 10, 1644
- 2011, MMWR. Morbidity and mortality weekly report, 60, 243
Cited by
The global problem of antifungal resistance: prevalence, mechanisms, and management
Perlin, D. S., Rautemaa-Richardson, R., & Alastruey-Izquierdo, A. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30316-x · Cited by 1,055
Pfaller, M. A., Diekema, D. J., Turnidge, J. D., Castanheira, M., & Jones, R. N. (2019) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofy358 · Cited by 825
“tropicalis is generally susceptible to fluconazole [103], and prophylaxis with this agent has been associated with a decrease in the incidence of C.”
BackgroundMultidrug-Resistant Candida: Epidemiology, Molecular Mechanisms, and Treatment
Arendrup, M. C., & Patterson, T. F. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix131 · Cited by 707
Epidemiology and risk factors for invasive candidiasis
Yapar, N. (2014) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s40160 · Cited by 610
Chowdhary, A., Prakash, A., Sharma, C., Kordalewska, M., Kumar, A., Sarma, S., Tarai, B., Singh, A., Upadhyaya, G., Upadhyay, S., et al. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx480 · Cited by 577
Changes in the epidemiological landscape of invasive candidiasis
Lamoth, F., Lockhart, S. R., Berkow, E. L., & Calandra, T. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx444 · Cited by 547
Self-citationFluconazole resistance in Candida species: a current perspective
Berkow, E., & Lockhart, S. (2017) · Infection and Drug Resistance · doi:10.2147/idr.s118892 · Cited by 542
Self-citationAntimicrobial Agents and Chemotherapy
(2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac · Cited by 485
Mechanisms of Candida Biofilm Drug Resistance
Taff, H. T., Mitchell, K. F., Edward, J. A., & Andes, D. R. (2013) · Future Microbiology · doi:10.2217/fmb.13.101 · Cited by 422
Emerging Threats in Antifungal-Resistant Fungal Pathogens
Sanglard, D. (2016) · Frontiers in Medicine · doi:10.3389/fmed.2016.00011 · Cited by 416
“In a study from two different areas between 2008 and 2011, resistance to agents, such as fluconazole (CBP: ≥64 μg/ml) or echinocandins (CBP: ≥4 μg/ml), ranged between 1 and 2% in bloodstream isolates (24).”
BackgroundPfaller, M. A., Andes, D. R., Diekema, D. J., Horn, D. L., Reboli, A. C., Rotstein, C., Franks, B., & Azie, N. E. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101510 · Cited by 396
Antifungal drug resistance among Candida species: mechanisms and clinical impact
Sanguinetti, M., Posteraro, B., & Lass‐Flörl, C. (2015) · Mycoses · doi:10.1111/myc.12330 · Cited by 394
Echinocandin resistance in Candida.
Perlin, D. S. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ791 · Cited by 374
Epidemiology of candidemia in Latin America: a laboratory-based survey
Nucci, M., Queiroz-Telles, F., Alvarado-Matute, T., Tiraboschi, I. N., Cortes, J., Zurita, J., Guzman-Blanco, M., Santolaya, M. E., Thompson, L., Sifuentes-Osornio, J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059373 · Cited by 374
“parapsilosis is very prevalent in Latin America, and is distributed in all age strata, contrasting to studies from other parts of the globe, in which this species is more frequent among neonates [39].”
ResultThe Changing Epidemiology of Invasive Fungal Infections
Enoch, D. A., Yang, H., Aliyu, S. H., & Micallef, C. (2017) · Methods in Molecular Biology · doi:10.1007/978-1-4939-6515-1_2 · Cited by 370
Epidemiology of Carbapenem-Resistant Enterobacteriaceae in 7 US Communities, 2012-2013
Guh, A. Y., Bulens, S. N., Mu, Y., Jacob, J. T., Reno, J., Scott, J., Wilson, L. E., Vaeth, E., Lynfield, R., Shaw, K. M., et al. (2015) · JAMA · doi:10.1001/jama.2015.12480 · Cited by 369
Nosocomial Fungal Infections: Epidemiology, Infection Control, and Prevention
Alangaden, G. J. (2011) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2010.11.003 · Cited by 337
Morbidity and mortality of candidaemia in Europe: an epidemiologic meta-analysis
Koehler, P., Stecher, M., Cornely, O. A., Koehler, D., Vehreschild, M. J. G. T., Bohlius, J., Wisplinghoff, H., & Vehreschild, J. J. (2019) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2019.04.024 · Cited by 336
The Candida Pathogenic Species Complex
Turner, S. A., & Butler, G. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a019778 · Cited by 336
“Recent studies suggest that at least in the United States, the incidence of all Candida species among neonates is decreasing, which may be related to standardization of central line care (Fridkin et al. 2006; Chitnis et al. 2012; Cleveland et al. 2012).”
BackgroundMechanisms of echinocandin antifungal drug resistance
Perlin, D. S. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12831 · Cited by 313
The French Mycosis Study Group, Lortholary, O., Renaudat, C., Sitbon, K., Madec, Y., Denoeud-Ndam, L., Wolff, M., Fontanet, A., Bretagne, S., & Dromer, F. (2014) · Intensive Care Medicine · doi:10.1007/s00134-014-3408-3 · Cited by 312
Cleveland, A. A., Harrison, L. H., Farley, M. M., Hollick, R., Stein, B., Chiller, T. M., Lockhart, S. R., & Park, B. J. (2015) · PLOS ONE · doi:10.1371/journal.pone.0120452 · Cited by 304
“The methods of surveillance have been previously described [9].”
BackgroundMethodSelf-citationPuig-Asensio, M., Padilla, B., Garnacho-Montero, J., Zaragoza, O., Aguado, J. M., Zaragoza, R., Montejo, M., Muñoz, P., Ruiz-Camps, I., Cuenca-Estrella, M., et al. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12380 · Cited by 299
“epidemiological trend towards the increasing relevance of the elderly population as the most important age-specific group affected by candidaemia [2,4,12].”
BackgroundThe global burden of fungal diseases
Vallabhaneni, S., Mody, R. K., Walker, T., & Chiller, T. (2016) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2015.10.004 · Cited by 292
Self-citationCandida albicans biofilm–induced vesicles confer drug resistance through matrix biogenesis
Zarnowski, R., Sanchez, H., Covelli, A. S., Dominguez, E., Jaromin, A., Bernhardt, J., Mitchell, K. F., Heiss, C., Azadi, P., Mitchell, A., et al. (2018) · PLOS Biology · doi:10.1371/journal.pbio.2006872 · Cited by 260
Epidemiology of Invasive Fungal Disease in Children
Pana, Z. D., Roilides, E., Warris, A., Groll, A. H., & Zaoutis, T. (2017) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/pix046 · Cited by 260
“IFD IN NICU PATIENTS A significant increase in the incidence of IC was reported initially during the 1990s to be temporally associated with increased survival rates of premature very-low-birth-weight neonates, but in the past 15 years, there has been an overall decrease in neonatal IC within European countries and the…”
BackgroundResultInfluentialUpdate on antifungal resistance in Aspergillus and Candida
Arendrup, M. C. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12513 · Cited by 240
“[57,65–70].”
Pfaller, M. A., Messer, S. A., Woosley, L. N., Jones, R. N., & Castanheira, M. (2013) · Journal of Clinical Microbiology · doi:10.1128/jcm.00308-13 · Cited by 237
Pham, C. D., Iqbal, N., Bolden, C. B., Kuykendall, R. J., Harrison, L. H., Farley, M. M., Schaffner, W., Beldavs, Z. G., Chiller, T. M., Park, B. J., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03255-14 · Cited by 231
Self-citationEvolutionary Emergence of Drug Resistance in Candida Opportunistic Pathogens
Ksiezopolska, E., & Gabaldón, T. (2018) · Genes · doi:10.3390/genes9090461 · Cited by 230
Arendrup, M. C., Dzajic, E., Jensen, R. H., Johansen, H. K., Kjaldgaard, P., Knudsen, J. D., Kristensen, L., Leitz, C., Lemming, L. E., Nielsen, L., et al. (2013) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12212 · Cited by 206
“high mortality in patients in whom antifungal treatment has been delayed [1–8].”
BackgroundToda, M., Williams, S. R., Berkow, E. L., Farley, M. M., Harrison, L. H., Bonner, L., Marceaux, K. M., Hollick, R., Zhang, A. Y., Schaffner, W., et al. (2019) · MMWR Surveillance Summaries · doi:10.15585/mmwr.ss6808a1 · Cited by 198
Self-citationFungal Resistance to Echinocandins and the MDR Phenomenon in Candida glabrata
Healey, K. R., & Perlin, D. S. (2018) · Journal of Fungi · doi:10.3390/jof4030105 · Cited by 194
“glabrata ST distribution in Atlanta area hospitals changed significantly between 1992 and 2008, the time period that includes the introduction of echinocandins [101].”
BackgroundFungal resistance to echinocandins and the MDR phenomenon in Candida glabrata
Healey, K., & Perlin, D. S. (2018) · doi:10.20944/preprints201808.0306.v1 · Cited by 194
Risk factors for candidemia: a prospective matched case-control study
FUNGINOS, T., Poissy, J., Groups, A. F. S., Damonti, L., Bignon, A., Khanna, N., Von Kietzell, M., Boggian, K., Neofytos, D., Vuotto, F., et al. (2020) · Critical Care · doi:10.1186/s13054-020-2766-1 · Cited by 188
Vallabhaneni, S., Cleveland, A. A., Farley, M. M., Harrison, L. H., Schaffner, W., Beldavs, Z. G., Derado, G., Pham, C. D., Lockhart, S. R., & Smith, R. M. (2015) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofv163 · Cited by 187
Self-citationThe Threat of Antimicrobial Resistance on the Human Microbiome
Brinkac, L., Voorhies, A., Gomez, A., & Nelson, K. E. (2017) · Microbial Ecology · doi:10.1007/s00248-017-0985-z · Cited by 186
“The global prevalence of azole resistance inAspergillus is estimated to be 3–6%, and approximately 7% of all Candida bloodstream isolates are resistant to fluconazole [8], with echinocandin resistance on the rise [3].”
BackgroundColombo, A. L., Guimarães, T., Sukienik, T., Pasqualotto, A. C., Andreotti, R., Queiroz-Telles, F., Nouér, S. A., & Nucci, M. (2014) · Intensive Care Medicine · doi:10.1007/s00134-014-3400-y · Cited by 183
Andes, D. R., Safdar, N., Baddley, J. W., Alexander, B., Brumble, L., Freifeld, A., Hadley, S., Herwaldt, L., Kauffman, C., Lyon, G. M., et al. (2016) · Transplant Infectious Disease · doi:10.1111/tid.12613 · Cited by 182
Self-citationEpidemiology and molecular mechanisms of antifungal resistance in Candida and Aspergillus
Gonçalves, S. S., Souza, A. C. R., Chowdhary, A., Meis, J. F., & Colombo, A. L. (2016) · Mycoses · doi:10.1111/myc.12469 · Cited by 180
Contributions of the Biofilm Matrix to Candida Pathogenesis
Nett, J. E., & Andes, D. R. (2020) · Journal of Fungi · doi:10.3390/jof6010021 · Cited by 157
Incidence and species distribution of candidaemia in Asia: a laboratory-based surveillance study
Tan, B. H., Chakrabarti, A., Li, R. Y., Patel, A. K., Watcharananan, S. P., Liu, Z., Chindamporn, A., Tan, A. L., Sun, P.-L., Wu, U.-I., et al. (2015) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2015.06.010 · Cited by 176
“glabrata is the most frequently isolated non-albicans Candida species [1,3,6,12,17].”
BackgroundInfluentialFKS Mutant Candida glabrata: Risk Factors and Outcomes in Patients With Candidemia
Beyda, N. D., John, J., Kilic, A., Alam, M. J., Lasco, T. M., & Garey, K. W. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu407 · Cited by 174
T2MR and T2Candida: novel technology for the rapid diagnosis of candidemia and invasive candidiasis
Pfaller, M. A., Wolk, D. M., & Lowery, T. J. (2016) · Future Microbiology · doi:10.2217/fmb.15.111 · Cited by 157
Suleyman, G., & Alangaden, G. J. (2016) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2016.07.008 · Cited by 167
Resistance of Candida spp. to antifungal drugs in the ICU: where are we now?
Maubon, D., Garnaud, C., Calandra, T., Sanglard, D., & Cornet, M. (2014) · Intensive Care Medicine · doi:10.1007/s00134-014-3404-7 · Cited by 162
Safety and pharmacokinetics of CD101 IV, a novel echinocandin, in healthy adults
Sandison, T., Ong, V., Lee, J., & Thye, D. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01627-16 · Cited by 161
Nosocomial Candidiasis: Antifungal Stewardship and the Importance of Rapid Diagnosis
Pfaller, M. A., & Castanheira, M. (2015) · Medical Mycology · doi:10.1093/mmy/myv076 · Cited by 161
“In situations where such data are not available, efforts should be made to collect local information and in the interim data from national and regional surveys may be useful [5,94,97,98].”
BackgroundInfluentialCastanheira, M., Messer, S. A., Rhomberg, P. R., & Pfaller, M. A. (2016) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2016.02.009 · Cited by 159
“These fungal infections have high associated mortality rates and elevated cost for healthcare systems (Cleveland et al., 2012).”
BackgroundGeddes‐McAlister, J., & Shapiro, R. S. (2019) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13739 · Cited by 159
Anaissie, E., & Bodey, G. P. (1989) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(20)30311-1 · Cited by 159
Vitamin D and Infectious Diseases: Simple Bystander or Contributing Factor?
Gois, P. H. F., Ferreira, D., Olenski, S., & Seguro, A. C. (2017) · Nutrients · doi:10.3390/nu9070651 · Cited by 148
Beardsley, J., Halliday, C. L., Chen, S. C.-A., & Sorrell, T. C. (2018) · Future Microbiology · doi:10.2217/fmb-2018-0059 · Cited by 124
Current status of antifungal resistance and its impact on clinical practice
Alcazar‐Fuoli, L., & Mellado, E. (2014) · British Journal of Haematology · doi:10.1111/bjh.12896 · Cited by 117
“While antifungal drug resistance among C. albicans isolates remains low (Lockhart et al, 2012), C. glabrata and C. krusei have emerged as important and potentially antifungal resistant causes of candidaemia (Cleveland et al, 2012).”
BackgroundThe risk and clinical outcome of candidemia depending on underlying malignancy
The French Mycoses Study Group, Lortholary, O., Renaudat, C., Sitbon, K., Desnos-Ollivier, M., Bretagne, S., & Dromer, F. (2017) · Intensive Care Medicine · doi:10.1007/s00134-017-4743-y · Cited by 134
The Mycobiome in Health and Disease: Emerging Concepts, Methodologies and Challenges
Tiew, P. Y., Aogáin, M. M., Ali, N. A. B. M., Thng, K. X., Goh, K., Lau, K. J. X., & Chotirmall, S. H. (2020) · Mycopathologia · doi:10.1007/s11046-019-00413-z · Cited by 138
Florio, W., Tavanti, A., Barnini, S., Ghelardi, E., & Lupetti, A. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01097 · Cited by 134
“, a number of emerging fungal pathogens has been isolated with increased frequency, including Candida glabrata (Cleveland et al., 2012; Pfaller et al., 2014), Trichosporon spp.”
BackgroundPreclinical Evaluation of the Stability, Safety, and Efficacy of CD101, a Novel Echinocandin
Ong, V., Hough, G., Schlosser, M., Bartizal, K., Balkovec, J. M., James, K. D., & Krishnan, B. R. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00701-16 · Cited by 126
Quindós, G., Marcos‐Arias, C., San-Millán, R., Mateo, E., & Eraso, E. (2018) · International Microbiology · doi:10.1007/s10123-018-0014-1 · Cited by 131
Epidemiology of hospitalizations associated with invasive candidiasis, United States, 2002-20121
Strollo, S., Lionakis, M. S., Adjemian, J., Steiner, C. A., & Prevots, D. R. (2016) · Emerging Infectious Diseases · doi:10.3201/eid2301.161198 · Cited by 129
“Invasive infections might persist in organs after infections are cleared from the bloodstream, and ≈8% of candidemia cases show reoccurrence (13).”
BackgroundCandida glabrata Biofilms: How Far Have We Come?
Rodrigues, C., Rodrigues, M., Silva, S., & Henriques, M. (2017) · Journal of Fungi · doi:10.3390/jof3010011 · Cited by 129
“krusei emerging as important and potentially antifungal resistant causes of candidaemia [56].”
BackgroundReview on Current Status of Echinocandins Use
Mroczyńska, M., & Brillowska‐Dąbrowska, A. (2020) · Antibiotics · doi:10.3390/antibiotics9050227 · Cited by 128
Pfaller, M. A., Rhomberg, P. R., Messer, S. A., Jones, R. N., & Castanheira, M. (2015) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2015.04.008 · Cited by 127
“glabrata, large-scale and continuous surveillance programs are also useful in detecting emerging resistance among usually susceptible species of Candida as well as other less common yeasts and molds associated with invasive fungal infections (IFIs) (Arendrup et al., 2013; Chen et al., 2009; Cleveland et al., 2012; Die…”
BackgroundPrasath, K. G., Tharani, H., Kumar, M. S., & Pandian, S. K. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.00864 · Cited by 127
Coordination of fungal biofilm development by extracellular vesicle cargo
Zarnowski, R., Noll, A., Chevrette, M. G., Sanchez, H., Jones, R., Anhalt, H., Fossen, J., Jaromin, A., Currie, C., Nett, J. E., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26525-z · Cited by 123
Souza, A. C. R., Fuchs, B. B., Pinhati, H. M. S., Siqueira, R. A., Hagen, F., Meis, J. F., Mylonakis, E., & Colombo, A. L. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01177-15 · Cited by 121
Da Matta, D., Souza, A., & Colombo, A. (2017) · Journal of Fungi · doi:10.3390/jof3020024 · Cited by 104
Pinhati, H. M. S., Casulari, L. A., Souza, A. C. R., Siqueira, R. A., Damasceno, C. M. G., & Colombo, A. L. (2016) · BMC Infectious Diseases · doi:10.1186/s12879-016-1767-9 · Cited by 102
Asmundsdottir, L. R., Erlendsdottir, H., & Gottfredsson, M. (2013) · Journal of Clinical Microbiology · doi:10.1128/jcm.02566-12 · Cited by 100
Castanheira, M., Deshpande, L. M., Messer, S. A., Rhomberg, P. R., & Pfaller, M. A. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2019.09.003 · Cited by 105
The Candidemia Study Group, Barchiesi, F., Orsetti, E., Gesuita, R., Skrami, E., & Manso, E. (2015) · Infection · doi:10.1007/s15010-015-0845-z · Cited by 113
Drug resistance mechanisms and their regulation in non-albicans Candida species
Kołaczkowska, A., & Kołaczkowski, M. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv445 · Cited by 87
Grossman, N. T., Pham, C. D., Cleveland, A. A., & Lockhart, S. R. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04613-14 · Cited by 112
“parapsilosis (11) and the threat that fluconazole resistance could pose in a clonally expanding population, little is known about the molecular mechanisms of C.”
BackgroundSelf-citationA 1-year prospective survey of candidemia in Italy and changing epidemiology over one decade
Tortorano, A. M., Prigitano, A., Lazzarini, C., Passera, M., Deiana, M. L., Cavinato, S., De Luca, C., Grancini, A., Lo Cascio, G., Ossi, C., et al. (2013) · Infection · doi:10.1007/s15010-013-0455-6 · Cited by 110
“The increased overall rate of candidemia, which has also been observed in other countries [2, 14, 15], may be driven by advances in medical, surgical and intensive care procedures that prolong the survival of critically ill patients Table 5 In vitro susceptibilities of 464 Candida bloodstream isolates”
Epidemiology of Invasive Candidiasis
Bays, D., Jenkins, E., Lyman, M., Chiller, T., Strong, N., Ostrosky-Zeichner, L., Hoenigl, M., Pappas, P., & Thompson, G. (2024) · Clinical Epidemiology · doi:10.2147/clep.s459600 · Cited by 109
“27,51,52 In Europe, the 30-day mortality rate of IC was slightly higher at 38–42%.”
BackgroundSelf-citationUncommon Candida Species Fungemia among Cancer Patients, Houston, Texas, USA
Jung, D. S., Farmakiotis, D., Jiang, Y., Tarrand, J. J., & Kontoyiannis, D. P. (2015) · Emerging Infectious Diseases · doi:10.3201/eid2111.150404 · Cited by 97
“For example, higher rates of echinocandin resistance are reported from oncology and transplantation centers in the United States (23–25) compared with population-based cohorts (4).”
BackgroundInfluentialCandida auris for the Clinical Microbiology Laboratory: Not Your Grandfather's Candida Species
Lockhart, S. R., Berkow, E. L., Chow, N., & Welsh, R. M. (2017) · Clinical Microbiology Newsletter · doi:10.1016/j.clinmicnews.2017.06.003 · Cited by 93
Self-citationHospital-Associated Multicenter Outbreak of Emerging Fungus Candida auris, Colombia, 2016
Armstrong, P. A., Rivera, S. M., Escandon, P., Caceres, D. H., Chow, N., Stuckey, M. J., Díaz, J., Gomez, A., Vélez, N., Espinosa-Bode, A., et al. (2019) · Emerging Infectious Diseases · doi:10.3201/eid2507.180491 · Cited by 92
Self-citationNishimoto, A. T., Sharma, C., & Rogers, P. D. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz400 · Cited by 102
Current Epidemiology of Candida Infection
Lockhart, S. R. (2014) · Clinical Microbiology Newsletter · doi:10.1016/j.clinmicnews.2014.08.001 · Cited by 101
Self-citationPfaller, M. A., Jones, R. N., & Castanheira, M. (2014) · Mycoses · doi:10.1111/myc.12206 · Cited by 93
Echinocandin Resistance, Susceptibility Testing and Prophylaxis: Implications for Patient Management
Perlin, D. S. (2014) · Drugs · doi:10.1007/s40265-014-0286-5 · Cited by 99
“Recent CDC surveillance indicates that [60 % of candidemia patients now receive an echinocandin [4].”
Posteraro, B., Efremov, L., Leoncini, E., Amore, R., Posteraro, P., Ricciardi, W., & Sanguinetti, M. (2015) · Journal of Clinical Microbiology · doi:10.1128/jcm.00802-15 · Cited by 97
Goemaere, B., Becker, P., Van Wijngaerden, E., Maertens, J., Spriet, I., Hendrickx, M., & Lagrou, K. (2018) · Mycoses · doi:10.1111/myc.12714 · Cited by 91
Sadeghi, G., Ebrahimi-Rad, M., Mousavi, S. F., Shams-Ghahfarokhi, M., & Razzaghi-Abyaneh, M. (2018) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2017.12.008 · Cited by 96
Chisanga, M., Muhamadali, H., Ellis, D. I., & Goodacre, R. (2018) · Applied Spectroscopy · doi:10.1177/0003702818764672 · Cited by 92
“105 Within the last few years, SERS has been shown to be effective in detection and identification of specific pathogenic microorganisms associated with UTIs, 97,106 pneumonia, 107 and anthrax, 95,108 in order to guide personalized clinical intervention.”
BackgroundPfaller, M. A., Castanheira, M., Messer, S. A., Rhomberg, P. R., & Jones, R. N. (2014) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2014.03.004 · Cited by 92
Chang, W., Liu, J., Zhang, M., Shi, H., Zheng, S., Jin, X., Gao, Y., Wang, S., Ji, A., & Lou, H. (2018) · Nature Communications · doi:10.1038/s41467-018-07633-9 · Cited by 91
Singh, A. K., Singh, P. K., de Groot, T., Kumar, A., Mathur, P., Tarai, B., Sachdeva, N., Upadhyaya, G., Sarma, S., Meis, J. F. G. M., et al. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz029 · Cited by 87
Gómez-Gaviria, M., Ramírez-Sotelo, U., & Mora-Montes, H. M. (2022) · Journal of Fungi · doi:10.3390/jof9010011 · Cited by 87
“glabrata, causing hematogenous infections [16,17].”
The Elusive Anti-Candida Vaccine: Lessons From the Past and Opportunities for the Future
Tso, G. H. W., Reales-Calderon, J. A., & Pavelka, N. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00897 · Cited by 78
“Despite the best available standards of care, the incidence of candidemia, a sign of invasive or systemic candidiasis, is on the rise in the US (8) and mortality rates often exceed 50% despite use of antifungal drugs (9).”
BackgroundPuig‐Asensio, M., Ruíz-Camps, I., Fernández‐Ruiz, M., Aguado, J. M., Muñóz, P., Valerio, M., Delgado‐Iribarren, A., Merino, P., Bereciartúa, E., Fortün, J., et al. (2015) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2014.12.027 · Cited by 82
Benedict, K., Roy, M., Kabbani, S., Anderson, E. J., Farley, M. M., Harb, S., Harrison, L. H., Bonner, L., Wadu, V. L., Marceaux, K., et al. (2018) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piy009 · Cited by 81
“Recent reports documented a decline in candidemia rates among infants aged <1 year [2, 10].”
BackgroundSelf-citationYang, Z.-T., Wu, L., Liu, X.-Y., Zhou, M., Li, J., Wu, J.-Y., Cai, Y., Mao, E.-Q., Chen, E.-Z., & Lortholary, O. (2014) · BMC Infectious Diseases · doi:10.1186/1471-2334-14-241 · Cited by 71
Antifungal drug resistance in Candida species
Morace, G., Perdoni, F., & Borghi, E. (2014) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2014.09.002 · Cited by 80
Megri, Y., Arastehfar, A., Boekhout, T., Daneshnia, F., Hörtnagl, C., Sartori, B., Hafez, A., Pan, W., Lass-Flörl, C., & Hamrioui, B. (2020) · Antimicrobial Resistance & Infection Control · doi:10.1186/s13756-020-00710-z · Cited by 65
Posteraro, B., Spanu, T., Fiori, B., De Maio, F., De Carolis, E., Giaquinto, A., Prete, V., De Angelis, G., Torelli, R., D'Inzeo, T., et al. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00285-15 · Cited by 72
“) were recently shown to be the cause of twothirds of all cases of candidemia in a population-based laboratory study (14).”
BackgroundRobbins, N., Spitzer, M., Yu, T., Cerone, R. P., Averette, A. K., Bahn, Y.-S., Heitman, J., Sheppard, D. C., Tyers, M., & Wright, G. D. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.10.018 · Cited by 78
Dominguez, E., Zarnowski, R., Sanchez, H., Covelli, A. S., Westler, W. M., Azadi, P., Nett, J., Mitchell, A. P., & Andes, D. R. (2018) · mBio · doi:10.1128/mbio.00451-18 · Cited by 77
What are the 100 most cited fungal genera?
Bhunjun, C. S., Chen, Y. J., Phukhamsakda, C., Boekhout, T., Groenewald, J. Z., McKenzi, E. H. C., Francisco, E. C., Frisvad, J. C., Groenewald, M., Hurdeal, V. G., et al. (2024) · Studies in Mycology · doi:10.3114/sim.2024.108.01 · Cited by 77
Metadata
- Authors
- Cleveland, A. A., Farley, M. M., Harrison, L. H., Stein, B., Hollick, R., Lockhart, S. R., Magill, S. S., Derado, G., Park, B. J., & Chiller, T. M.
- Affiliations
- Centers for Disease Control and Prevention (US)
- ORCID
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-08-14
- Volume
- 55
- Issue
- 10
- Pages
- 1352-1361
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2157512355
- Cited by
- 366
- References
- 138
- Citations by year
- 2026: 7 · 2025: 9 · 2024: 17 · 2023: 16 · 2022: 23 · 2021: 32 · 2020: 35 · 2019: 21 · 2018: 42 · 2017: 35 · 2016: 28 · 2015: 44 · 2014: 33 · 2013: 19 · 2012: 2
- FWCI
- 21.64
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (CC999999)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Keywords
- candidemia, candidemia incidence, antifungal resistance, fluconazole resistance, echinocandin resistance, Candida glabrata, multidrug resistance, infants, older adults, epidemiological trends, antifungal prophylaxis, infection control, catheter-related infection, Atlanta, Baltimore
- MeSH terms
- Adolescent, Adult, Aged, Antifungal Agents, Candida, Child, Child, Preschool, Female, Georgia, Humans, Infant, Male, Middle Aged, Population Surveillance, Prospective Studies, Baltimore, Incidence, Drug Resistance, Fungal, Candidemia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.